Lee's Pharmaceutical Holdings Ltd
Company Profile
Business description
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue; and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
Contact
Hong Kong Science Park
1st Floor, Building 20E, Phase 3
Shatin
Hong Kong
HKGT: +852 23141282
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,094
Stocks News & Analysis
stocks
Australia’s largest gold miner downgraded on a falling gold price
stocks
Cheap ASX share pays a heavy price for NRL rights
stocks
The World Cup stock you’ve never heard of
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.00 | 6.60 | 0.07% |
| CAC 40 | 8,314.77 | 24.19 | -0.29% |
| DAX 40 | 25,029.03 | 38.06 | -0.15% |
| Dow JONES (US) | 52,637.01 | 149.60 | 0.29% |
| FTSE 100 | 10,495.06 | 2.23 | -0.02% |
| HKSE | 24,182.37 | 7.25 | 0.03% |
| NASDAQ | 26,281.61 | 74.72 | 0.29% |
| Nikkei 225 | 67,242.73 | 1,315.00 | -1.92% |
| NZX 50 Index | 13,723.20 | 62.47 | -0.45% |
| S&P 500 | 7,575.39 | 31.75 | 0.42% |
| S&P/ASX 200 | 8,808.50 | 11.70 | 0.13% |
| SSE Composite Index | 3,913.79 | 82.37 | -2.06% |